NBIX:NGS-Neurocrine Biosciences Inc.

EQUITY | Drug Manufacturers | Nasdaq Global Select

Last Closing Price

USD 78.56

Change

+2.68 (+3.53)%

Market Cap

USD 6.95B

Volume

0.95M

Yahoo Analyst Target

USD 89.08 (13.39%)

STA Analyst Target

USD 82.96 (5.61%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

Neurocrine Biosciences Inc discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-01-18 )

Largest Industry Peers for Drug Manufacturers

Symbol Name Price(Change) Market Cap
WBA Walgreens Boots Alliance Inc.

+0.22 (+0.29%)

USD 75.29B
MYL Mylan N.V.

-0.27 (-0.58%)

USD 24.95B
HCM Hutchison China MediTech Limit..

+0.25 (+0.63%)

USD 5.28B
AKRX Akorn Inc.

-0.09 (-0.27%)

USD 4.13B
GWPH GW Pharmaceuticals Plc

-0.45 (-0.34%)

USD 3.35B
HZNP Horizon Pharma plc

+0.22 (+1.47%)

USD 2.49B
IRWD Ironwood Pharmaceuticals Inc.

+0.10 (+0.67%)

USD 2.25B
SUPN Supernus Pharmaceuticals Inc.

-2.95 (-6.34%)

USD 2.23B
AERI Aerie Pharmaceuticals Inc.

+0.50 (+0.87%)

USD 2.13B
MDCO The Medicines Company

-0.34 (-1.34%)

USD 1.82B

ETFs Containing NBIX

BBP Virtus LifeSci Biotech Pr.. 4.28 % 0.85 %

+0.06 (+0.18%)

USD 0.04B
FBT First Trust Amex Biotech .. 4.22 % 0.56 %

-0.38 (0.18%)

USD 1.31B
BTEC Principal Healthcare Inno.. 2.30 % 0.42 %

+0.06 (+0.18%)

USD 0.05B
XBI SPDR Series Trust S&P Bio.. 1.58 % 0.35 %

-0.13 (0.18%)

USD 4.61B
JHSC John Hancock Multifactor .. 0.44 % 0.00 %

-0.09 (0.18%)

USD 0.03B
SCHA Schwab U.S. Small-Cap 0.24 % 0.06 %

-0.46 (0.18%)

USD 6.85B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 1.25% 37% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.25% 37% F 41% F
Trailing 12 Months  
Capital Gain 86.87% 91% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.87% 91% A- 92% A-
Trailing 5 Years  
Capital Gain 753.91% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 753.91% 97% A+ 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 62.59% 90% A- 96% A
Dividend Return 62.59% 90% A- 96% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 78.52% 24% F 10% F
Risk Adjusted Return 79.71% 99% A+ 74% C
Market Capitalization 4.26B 97% A+ 92% A-

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -35.23 96% A 92% A-
Price/Book Ratio 20.14 8% F 5% F
Price / Cash Flow Ratio -11.67 96% A 95% A
Price/Free Cash Flow Ratio -40.08 96% A 92% A-
Management Effectiveness  
Return on Equity -61.87% 49% F 17% F
Return on Invested Capital -38.26% 58% F 21% F
Return on Assets -35.60% 55% F 18% F
Debt to Equity Ratio 52.25% 37% F 45% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector